An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Janux Therapeutics to Participate and Present at Upcoming Investor Conferences in September
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Janux Therapeutics, Inc. (NASDAQ: JANX) announced participation in two investor conferences. The first is Citi's 17th Annual BioPharma Conference on September 7, 2022, in Boston, Massachusetts, featuring in-person meetings. The second is the H.C. Wainwright 24th Annual Global Investment Conference, held virtually from September 12 to 15, 2022, with an on-demand fireside chat available starting September 12. Janux focuses on developing novel immunotherapies using its TRACTr and TRACIr platforms to combat cancer effectively.
Positive
None.
Negative
None.
SAN DIEGO--(BUSINESS WIRE)--
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will participate and present at two upcoming investor conferences. Details are as follows:
H.C. Wainwright 24th Annual Global Investment Conference Forum: Virtual Fireside Chat and Virtual Investor Meetings
Dates: Monday, September 12 to Thursday, September 15, 2022
The fireside chat will be available for on-demand viewing beginning September 12 at 7:00 a.m. ET via the Investors & Media section of Janux’s website. An archived replay of the webcast will be available on the website for approximately 90 days following the presentation.
About Janux Therapeutics
Janux Therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms to better treat patients suffering from cancer. Janux’s initial focus is on developing a novel class of T cell engagers (TCEs), and its lead product candidates are designed to target clinically validated drug targets. While TCE therapeutics have displayed potent anti-tumor activity in hematological cancers, developing TCEs to treat solid tumors have faced challenges due to the limitations of prior TCE technologies, namely (i) overactivation of the immune system leading to cytokine release syndrome, (ii) on-target, healthy tissue toxicities, and (iii) poor pharmacokinetics leading to short half-life. Janux is using its TRACTr platform technology to engineer product candidates designed to overcome these limitations by offering accuracy, stability, activity, modularity, and manufacturability. Janux is developing a broad pipeline with lead TRACTr programs targeting prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2). Janux is also applying its proprietary technology to develop a TRACIr costimulatory bispecific product candidate against programmed death-ligand 1 (PD-L1) and Cluster of Differentiation 28 (CD28) designed to further enhance the anti-tumor activity of T cells. For more information, please visit www.januxrx.com.
Media:
Jessica Yingling, Ph.D.
Little Dog Communications Inc. jessica@litldog.com
(858) 344-8091
Source: Janux Therapeutics, Inc.
FAQ
What investor conferences will Janux Therapeutics participate in September 2022?
Janux Therapeutics will participate in Citi's 17th Annual BioPharma Conference on September 7 and the H.C. Wainwright 24th Annual Global Investment Conference from September 12 to 15.
When will the fireside chat from H.C. Wainwright's conference be available for viewing?
The fireside chat will be available for on-demand viewing starting September 12, 2022, at 7:00 a.m. ET.
What is the focus of Janux Therapeutics' research and development?
Janux Therapeutics focuses on developing next-generation immunotherapies for cancer using its proprietary TRACTr and TRACIr platforms.
What are the lead product candidates of Janux Therapeutics?
How does Janux Therapeutics plan to improve cancer treatment?
Janux aims to improve cancer treatment by developing T cell engagers that overcome limitations of prior technologies, enhancing anti-tumor activity with fewer side effects.
